Navigation Links
Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis
Date:7/10/2014

BURLINGTON, Mass., July 10, 2014 /PRNewswire/ -- Decision Resources Group finds that over half of surveyed nephrologists report awareness of the U.S. Food and Drug Administration's (FDA) approval of Vifor Fresenius Medical Care Renal Pharma's new phosphate binder Velphoro, which was approved by the FDA in November 2013 for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.

Other key findings from the report entitled TreatmentTrends: Nephrology (US) Q2 2014:

  • Bundling: Based on mean ratings, surveyed nephrologists are under the most pressure from their dialysis unit to restrict measurement of nonessential labs, to use lower doses of erythropoiesis-stimulating agents (ESAs) and to have more stringent hemoglobin targets resulting in less ESA use. Surveyed nephrologists believe that the delay of inclusion of oral dialysis drugs into the end-stage renal disease payment bundle will similarly impact future use of phosphate binders, oral iron and Amgen's Sensipar.
  • IV Iron patient share in hemodialysis (HD): American Regent/Fresenius Medical Care's Venofer has significantly declined in reported HD patient share compared with this time period last year.
  • Nephrologists' perceptions of late-stage compounds in clinical development: The report discusses aided familiarity, interest and percentage of patients as likely candidates for 12 renal products in development after review of product profiles. New product profiles added to this quarter's report, include:
    • LaJolla Pharmaceutical's GCS-100: Nearly half of nephrologists report high interest in the product, which was higher than all other renal anemia and bone mineral metabolism products in late-stage development covered in this study.
    • GSK's GSK-1278863A: Nearly one-third of nephrologists report high interest in this oral renal anemia product.
    • Shield Therapeutics' ST-10: Nearly a third of nephrologists report high interest in this oral ferric iron therapy.
    • Amgen's Velcalcetide: Should this intravenous therapy for secondary hyperparathyroidism (SHPT) receive FDA approval, nephrologists expect significantly higher usage in the dialysis versus the CKD non-dialysis (ND) setting.
    • OPKO Health's Rayaldee: While familiarity is low, over 40 percent of nephrologists report high interest in this oral Vitamin D therapy used to treat SHPT being tested in CKD stage 3 and stage 4 patients, after review of a product profile.

Comments from Decision Resources Group Director Rob Dubman:

  • "Physicians are recalling lower number of pills as one of Velphoro's primary messages from sales representatives. Not surprisingly, we have found that in this and other studies that delivery attributes are not as important compared with efficacy and safety attributes." 

Additional Resources:

A special report that is expected to publish later this month entitled The Impact of New Iron-Based Phosphate Binders on the Hyperphosphatemia Market will also help manufacturers understand why and how Velphoro and Keryx Pharmaceutical's Zerenex will be used, if Zerenex receives FDA approval later this year.

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesgroup.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO


'/>"/>
SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
2. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
3. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
4. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
5. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
6. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
7. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
8. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
9. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
10. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
11. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Research and Markets has announced the addition of ... offering. ... report forecasts the global optical transceiver market to grow at a ... report covers the present scenario and the growth prospects of the ... the report considers the revenue generated from the shipment of optical ...
(Date:12/9/2016)...  Harmar Mobility, LLC announced today that Steven E. Dawson has been ... of Directors. Photo - http://photos.prnewswire.com/prnh/20161209/447552 ... Harmar ... Mr. Dawson,s executive career includes leadership roles managing ... of industries. He brings to the company deep operational and leadership expertise, ...
(Date:12/9/2016)... aTyr Pharma, Inc. (Nasdaq: LIFE ), a ... to address severe, rare diseases, today announced that senior management will ... Success Healthcare Conference at the InterContinental Barclay Hotel in ... 4:20 p.m. ET. About aTyr Pharma ... aTyr Pharma is engaged ...
Breaking Medicine Technology:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... The ... Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits and ... the District of Columbia as an education tool in the war against teen drug ...
(Date:12/9/2016)... ... December 09, 2016 , ... Mediaplanet today announces distribution of the latest ... readers to sign up as an organ donor for the 123,000 people in the ... organ donor can save up to 8 saves through organ donation and enhance many ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... "I had ... an inventor from Winchester, Va. "I thought that if the nebulizer had a more ... rather than fearing them." , He developed the patent-pending NEBY to avoid the need ...
(Date:12/8/2016)... ... 08, 2016 , ... The Florida Hospital Tampa Wound Healing ... Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the Institute ... and facilities have earned this distinction. This is the second time the Florida ...
(Date:12/8/2016)... ... 2016 , ... ZyDoc , a New York-based medical ... Capture Methods for Input to Electronic Health Records: A Comparative Usability Study” has ... usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s MediSapien™ natural ...
Breaking Medicine News(10 mins):